Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Illumina, Inc. is a publicly traded biotechnology company specializing in genomic sequencing and array-based technologies, operating primarily within the life sciences, biotechnology, and clinical diagnostics industries. The company’s core business is enabling the analysis of genetic variation and biological function, which supports research, clinical, and applied markets. Illumina’s offerings are widely used by academic institutions, pharmaceutical and biotechnology companies, clinical laboratories, and government organizations.
Illumina’s primary revenue drivers are the sale of next-generation sequencing (NGS) systems, consumables (such as reagents and flow cells), and informatics solutions, with consumables representing the largest and most recurring revenue stream. The company is uniquely positioned as a dominant provider of short-read sequencing technology, supported by a large installed base and high switching costs for customers. Founded in 1998, Illumina initially focused on array-based genotyping technologies and transitioned over time into sequencing, notably expanding its market leadership after acquiring Solexa, Inc. in 2007, which laid the foundation for its modern NGS platforms.
Business Operations
Illumina operates primarily through two reportable business segments: Core Illumina and GRAIL. The Core Illumina segment includes sequencing platforms, consumables, microarrays, and related services and software. Revenue is generated through instrument placements and ongoing consumable usage, with consumables accounting for the majority of segment revenue. The GRAIL segment focuses on blood-based multi-cancer early detection tests, although its financial performance and strategic role have been subject to regulatory scrutiny and structural change.
The company conducts business globally, with a strong emphasis on proprietary sequencing technologies, chemistry, optics, and bioinformatics. Illumina controls key intellectual property related to sequencing-by-synthesis technology. Its operations include wholly owned subsidiaries across manufacturing, sales, and R&D functions. Illumina maintains collaborations with pharmaceutical companies, research institutions, and clinical laboratories to expand sequencing applications in oncology, reproductive health, and population genomics.
Strategic Position & Investments
Illumina’s strategic direction centers on expanding access to genomic sequencing by lowering cost per genome, increasing throughput, and broadening clinical adoption. Growth initiatives include continued innovation in high-throughput platforms such as NovaSeq, scalable mid-throughput systems, and cloud-enabled informatics solutions. The company has emphasized clinical applications, including oncology, genetic disease screening, and population-scale genomics programs.
A major strategic event was the acquisition of GRAIL, Inc., completed in 2021, which aimed to position Illumina in the emerging multi-cancer early detection market. This transaction faced regulatory opposition in the U.S. and Europe, leading Illumina to announce plans to divest GRAIL. Outside of GRAIL, Illumina’s investments focus on internal R&D rather than large-scale acquisitions, with ongoing development in sequencing chemistry, workflow automation, and data analysis technologies.
Geographic Footprint
Illumina is headquartered in North America, with its principal executive offices in San Diego, California. The company has a significant operational and commercial presence in Europe, Asia-Pacific, and Greater China, supporting a globally diversified customer base. Manufacturing, R&D, and commercial operations are distributed across multiple countries to support regional demand and regulatory requirements.
International markets represent a substantial portion of Illumina’s revenue, with strong adoption in Western Europe, China, and Japan. The company also participates in large-scale national genomics initiatives and population health programs worldwide, reinforcing its influence in global research and clinical ecosystems.
Leadership & Governance
Illumina is led by an executive team with experience across life sciences, healthcare, and technology, emphasizing innovation, operational discipline, and regulatory compliance. The leadership philosophy focuses on advancing genomic science while expanding clinical utility and maintaining ethical standards in data use and patient care.
Key executives include:
- Jacob Thaysen – Chief Executive Officer
- Ankur Dhingra – Chief Financial Officer
- Susan Tousi – Chief Commercial Officer
- Mark Robinson – Chief Legal Officer and General Counsel
- Alex Aravanis – Chief Technology Officer
The company operates under a board-led governance structure consistent with U.S. public company standards, with oversight of strategy, risk management, and executive compensation aligned to long-term shareholder value.